# Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1

> **NCT02090322** · NA · UNKNOWN · sponsor: **Universidad Autonoma de San Luis Potosí** · enrollment: 60 (estimated)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **PROCEDURE:** Injection of bevacizumab intravitreal (Avastin)

## Key facts

- **NCT ID:** NCT02090322
- **Lead sponsor:** Universidad Autonoma de San Luis Potosí
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090322, "Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02090322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*